Immunocore’s (IMCR) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Immunocore (NASDAQ:IMCR) in a research note released on Monday morning,Benzinga reports. HC Wainwright currently has a $100.00 price target on the stock. HC Wainwright also issued estimates for Immunocore’s Q1 2027 earnings at $0.05 EPS, Q2 2027 earnings at $0.16 EPS, Q3 2027 earnings at $0.26 EPS and Q4 2027 earnings at $0.37 EPS.

A number of other research analysts also recently issued reports on IMCR. Mizuho set a $38.00 price target on shares of Immunocore in a research report on Thursday, February 19th. Zacks Research cut shares of Immunocore from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Jefferies Financial Group cut shares of Immunocore from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $48.00 to $33.00 in a report on Monday, March 16th. Needham & Company LLC increased their price objective on shares of Immunocore from $71.00 to $75.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Finally, Wall Street Zen cut shares of Immunocore from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $60.89.

Immunocore Trading Up 1.6%

Immunocore stock opened at $29.98 on Monday. The firm’s 50-day moving average is $31.51 and its 200-day moving average is $33.59. The company has a debt-to-equity ratio of 1.03, a quick ratio of 4.01 and a current ratio of 4.04. Immunocore has a 1 year low of $27.44 and a 1 year high of $40.71. The company has a market cap of $1.52 billion, a P/E ratio of -42.83 and a beta of 0.83.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($0.60) earnings per share (EPS) for the quarter. Immunocore had a negative return on equity of 9.20% and a negative net margin of 8.88%.The business had revenue of $104.48 million during the quarter. On average, equities analysts expect that Immunocore will post -0.97 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Leger Tina Amber St sold 1,000 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total value of $32,350.00. Following the sale, the insider owned 1,119 shares of the company’s stock, valued at $36,199.65. This trade represents a 47.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David M. Berman sold 5,965 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $192,967.75. Following the transaction, the insider directly owned 5,859 shares in the company, valued at approximately $189,538.65. The trade was a 50.45% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 19,137 shares of company stock valued at $619,082 in the last quarter. Company insiders own 10.40% of the company’s stock.

Hedge Funds Weigh In On Immunocore

Several large investors have recently bought and sold shares of IMCR. Leonteq Securities AG acquired a new position in Immunocore during the 4th quarter valued at about $30,000. GAMMA Investing LLC increased its stake in Immunocore by 51.6% during the 3rd quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock valued at $33,000 after buying an additional 311 shares during the period. Harbour Investments Inc. increased its stake in Immunocore by 60.2% during the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after buying an additional 388 shares during the period. Rockefeller Capital Management L.P. acquired a new position in Immunocore during the 4th quarter valued at about $47,000. Finally, Arax Advisory Partners increased its stake in Immunocore by 302.9% during the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock valued at $48,000 after buying an additional 1,042 shares during the period. Institutional investors and hedge funds own 84.50% of the company’s stock.

About Immunocore

Immunocore plc is a clinical?stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T?cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T?cell receptors against cancer) platform utilizes engineered, soluble T?cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease?associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma?associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.